Betaseron Sales Boost Schering's 9 Months
Better-than-expected sales of Schering AG's multiple sclerosis treatment Betaseron (interferon beta) boosted the German company's financial results for the first nine months of the year. Net profits were ahead 8.2% to 210 million Deutschemarks ($135.9 million), and sales advanced 14% to over 3.5 billion marks ($2.3 billion).
Betaseron turnover was 230 million marks in the nine-month period, exceeding the company's anticipated sales of around 200 million marks. The product is currently only available in the USA, but the company is hoping for approvals next year in Canada and some European countries. For the full year, sales of Betaseron are expected to reach 350 million marks. They were previously expected to be around 300 million marks.
Schering chairman Giuseppe Vita said that all the nine-month growth (17%) had been achieved abroad, while business inside Germany grew only 1% in the wake of pricing pressures. Sales in the USA, in contrast, soared 76%, driven by Betaseron.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze